Increased levels of plasma endothelin-1 in non-insulin dependent diabetic patients with retinopathy but without other diabetes-related organ damage

Laurenti, O.; Vingolo, E. M.; Desideri, Giovambattista; Ferri, Claudio; Bellini, Cesare; Cassone-Faldetta, M.; Santucci, A; Mattia, G. De

doi:10.1055/s-0029-1211795

Cited by 26 publications

(7 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In contrast, other researchers observed increased plasma IR-ET-1 levels in type 2 diabetes with retinopathy. 38,39 Nevertheless, the plasma IR-ET-1 levels do not seem to contribute significantly to the increased vitreous IR-ET-1 levels in patients with PDR.…”

Section: Discussionmentioning

confidence: 96%

Immunoreactive Endothelin-1 in the Vitreous Humor and Epiretinal Membranes of Patients With Proliferative Diabetic Retinopathy

Roldán-Pallarés

Rollín²,

Martínez-Montero³

et al. 2007

Retina

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 96%

Immunoreactive Endothelin-1 in the Vitreous Humor and Epiretinal Membranes of Patients With Proliferative Diabetic Retinopathy

Roldán-Pallarés

Rollín²,

Martínez-Montero³

et al. 2007

Retina

View full text Add to dashboard Cite

show abstract

“…have shown that the increased levels of ET-1 could contribute to retinopathy development or, more probably, represent a marker of this diabetes-related complication. [37]…”

Section: Circulating Biomarkers In Diabetic Retinopathymentioning

confidence: 99%

Circulating biomarkers in glaucoma, age-related macular degeneration, and diabetic retinopathy

Nath

Halder

Velpandian

2017

Indian J Ophthalmol

View full text Add to dashboard Cite

Biomarkers to predict the altering physiological conditions over the period leading toward the ocular disorders are of major importance in therapeutics. Isolation and validation of the biomarkers specific to ocular diseases are a challenging task. Glaucoma is a neurodegenerative disease of the eye where the correlation of biomarkers in circulating fluid may be made specific for the eye. However, conditions such as wet age-related macular degeneration (AMD) and proliferative diabetic retinopathy (DR), circulating biomarkers might be having some degree of overlap with other conditions like cancer where a common factor such as angiogenesis is involved. Diabetes, a systemic disorder affecting the target organs such as eye, kidney, heart, and nervous system can be predicted using common circulating biomarkers. However, these markers need to be validated along with various stages of disease progression to enable the possibility of targeted pharmacological interventions apart from good glycemic control alone. This review compiles the attempts made to correlate such circulating biomarkers in the ocular conditions such as glaucoma, AMD, and DR in the search for a surrogate marker for diagnostic and prognostic value. To make biomarkers for the common convenience, genetic markers are excluded from this review.

show abstract

“…Indeed, a positive correlation was reported for DR and cardiovascular inflammatory factors, highlighting that strategies focused to decrease inflammatory activity may prevent the development of vascular complications in type 1 diabetes (Schram et al, 2005). Of interest, increased plasma levels of Endothelin (ET-1), a potent endothelium-derived vasoconstrictive peptide, have been found in non-insulin-dependent diabetic (NIDDM) patients, prospecting ET-1 as new marker of vascular damage in diabetic subjects (Laurenti et al, 1997). Jacqueminet and coworkers proposed the peripheral blood MMP-9 levels as "a suitable substitute biomarker" of retinopathy in type-1 diabetes not associated with vascular complications (Jacqueminet et al, 2006).…”

Section: Biomarkers In Drmentioning

confidence: 99%

Biomarkers of Neurodegeneration and Precision Therapy in Retinal Disease

et al. 2021

View full text Add to dashboard Cite

Vision-threatening retinal diseases affect millions of people worldwide, representing an important public health issue (high social cost) for both technologically advanced and new-industrialized countries. Overall RD group comprises the retinitis pigmentosa, the age-related macular degeneration (AMD), the diabetic retinopathy (DR), and idiopathic epiretinal membrane formation. Endocrine, metabolic, and even lifestyles risk factors have been reported for these age-linked conditions that represent a “public priority” also in this COVID-19 emergency. Chronic inflammation and neurodegeneration characterize the disease evolution, with a consistent vitreoretinal interface impairment. As the vitreous chamber is significantly involved, the latest diagnostic technologies of imaging (retina) and biomarker detection (vitreous) have provided a huge input at both medical and surgical levels. Complement activation and immune cell recruitment/infiltration as well as detrimental intra/extracellular deposits occur in association with a reactive gliosis. The cell/tissue aging route shows a specific signal path and biomolecular profile characterized by the increased expression of several glial-derived mediators, including angiogenic/angiostatic, neurogenic, and stress-related factors (oxidative stress metabolites, inflammation, and even amyloid formation). The possibility to access vitreous chamber by collecting vitreous reflux during intravitreal injection or obtaining vitreous biopsy during a vitrectomy represents a step forward for an individualized therapy. As drug response and protein signature appear unique in each single patient, therapies should be individualized. This review addresses the current knowledge about biomarkers and pharmacological targets in these vitreoretinal diseases. As vitreous fluids might reflect the early stages of retinal sufferance and/or late stages of neurodegeneration, the possibility to modulate intravitreal levels of growth factors, in combination to anti-VEGF therapy, would open to a personalized therapy of retinal diseases.

show abstract

Increased levels of plasma endothelin-1 in non-insulin dependent diabetic patients with retinopathy but without other diabetes-related organ damage

Cited by 26 publications

References 0 publications

Immunoreactive Endothelin-1 in the Vitreous Humor and Epiretinal Membranes of Patients With Proliferative Diabetic Retinopathy

Immunoreactive Endothelin-1 in the Vitreous Humor and Epiretinal Membranes of Patients With Proliferative Diabetic Retinopathy

Circulating biomarkers in glaucoma, age-related macular degeneration, and diabetic retinopathy

Biomarkers of Neurodegeneration and Precision Therapy in Retinal Disease

Contact Info

Product

Resources

About